Back to first-pass browser

First-pass extracted concept

compound 21

Candidate: toolkit item1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

C21

Extracted Explainers

What the tool is doing

Compound 21 is presented as a novel DREADD actuator. In this study it also modulated sleep in wild-type mice that did not express DREADD receptors.

Source 1DOIPubMed

Resources required

Use requires chemogenetic actuator administration; the abstract reports 3 mg/kg dosing in mice with sleep assessed by EEG and EMG.

Source 1DOIPubMed

What problem it solves

It offers a newer actuator option for DREADD-based chemogenetic experiments.

Source 1DOIPubMed

What it does not solve

It does not eliminate off-target physiological effects, because the abstract reports sleep modulation despite lack of back-metabolism to clozapine.

Source 1DOIPubMed

Alternatives

The abstract contrasts compound 21 with CNO and references clozapine as a comparator for the sleep-pattern similarity seen with CNO.

Source 1DOIPubMed

Evidence Snippets

the novel DREADD actuator, compound 21 (C21, 3 mg/kg)
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1experimental recommendationsupports2023Source 1DOIPubMed

Chemogenetic experiments should include a DREADD-free control group injected with the same actuator.

Quoted textsource-backed
Therefore, any chemogenetic experiment should include a DREADD-free control group injected with the same CNO, C21, or newly developed actuator.
Claim 2mechanistic inferencesupports2023Source 1DOIPubMed

Back-metabolism to clozapine is not the sole mechanism underlying side effects of chemogenetic actuators.

Quoted textsource-backed
This implies that back-metabolism to clozapine is not the sole mechanism underlying side effects of chemogenetic actuators.
Claim 3off target effectsupports2023Source 1DOIPubMed

Compound 21 similarly modulates sleep in mice despite lacking back-metabolism to clozapine.

Quoted textsource-backed
Interestingly, we found that the novel DREADD actuator, compound 21 (C21, 3 mg/kg), similarly modulates sleep despite a lack of back-metabolism to clozapine.